Assessing the impact of various tuberculin PPD brands on bovine tuberculosis diagnosis.

Sci Rep

One Health Research Group, Facultad de Ciencias de la Salud, Universidad de las Américas (UDLA), Quito, Ecuador.

Published: March 2024

Although several brands of tuberculin purified protein derivatives (PPDs) are available for diagnosing bovine tuberculosis (bTB), comparative studies to determine their diagnostic accuracy are infrequent. In Ecuador we compared two different PPD brands for bTB diagnosis using skin testing and measuring skin thickness increase. Additionally, we evaluated four PPD brands, including those used for skin testing, in the Bovine Tuberculosis Interferon Gamma Test (IFN-γ test) measuring IFN-γ induction in whole blood. The study included 17 naturally tuberculosis-infected PPD and IFN-γ test positive bovines. Both the field and laboratory results showed significant differences in classifying the 17 bovines as bTB positive or negative. We hypothesize that several factors, such as the genetic background of the cows, sensitization to environmental mycobacteria, M. bovis strains involved in the bTB infection, and the manufacturing procedures of the PPDs, could have influenced the immune reaction toward the different tuberculin PPD brands. Our study emphasizes the necessity for comparative studies aimed at determining the diagnostic accuracy of PPD brands for bTB diagnosis as well as the development of standardized methods for PPD production and potency determination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908831PMC
http://dx.doi.org/10.1038/s41598-024-52089-1DOI Listing

Publication Analysis

Top Keywords

ppd brands
16
bovine tuberculosis
12
tuberculin ppd
8
comparative studies
8
diagnostic accuracy
8
brands btb
8
btb diagnosis
8
skin testing
8
ifn-γ test
8
ppd
6

Similar Publications

Article Synopsis
  • The concept of "obstetric violence" has gained traction globally, highlighting power imbalances in reproductive health and challenging the perception of pregnancy and childbirth as merely medical events.
  • The discussion extends to include post-partum obstetric violence, which has been largely overlooked, emphasizing the impact of pharmaceutical treatments for issues like postpartum depression (PPD) on women's health.
  • The approval of zuranolone, the first pill for PPD, exemplifies the risks of framing emotional distress as purely biochemical, which could underplay the socio-political factors at play and result in harmful consequences for women.
View Article and Find Full Text PDF

Despite evidence of benefits beyond those of oral antipsychotics, long-acting injectable antipsychotics (LAIs) are underused in schizophrenia treatment. Underuse may be partially a result of misconceptions held by some healthcare professionals (HCPs) pertaining to LAIs. A panel of four experts convened between January 2022 and May 2022 to identify these misconceptions, and example cases or scenarios were created to illustrate common clinical situations relevant to these beliefs.

View Article and Find Full Text PDF

What Is This Summary About?: A medicine called (brand name TRODELVY) has been proven to be an effective treatment for metastatic triple-negative breast cancer (mTNBC for short). Metastatic breast cancer is cancer that has spread to other parts of the body. In mTNBC, the breast cancer cells do not have 3 common proteins on the cell surface, called receptors.

View Article and Find Full Text PDF

Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that is approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. In the phase 3, randomized, double-blind RIsperidone Subcutaneous Extended-release (RISE) study, TV-46000 once monthly (q1m) and once every 2 months (q2m) significantly prolonged time to impending relapse compared with placebo [5.0-fold (q1m) and 2.

View Article and Find Full Text PDF

Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement.

Pain

October 2024

Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.

Pragmatic, randomized, controlled trials hold the potential to directly inform clinical decision making and health policy regarding the treatment of people experiencing pain. Pragmatic trials are designed to replicate or are embedded within routine clinical care and are increasingly valued to bridge the gap between trial research and clinical practice, especially in multidimensional conditions, such as pain and in nonpharmacological intervention research. To maximize the potential of pragmatic trials in pain research, the careful consideration of each methodological decision is required.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!